| Company | Value | Change | %Change |
|---|
The company’s net profit stood at ₹58 crore, down 20.5% from ₹73 crore in the same quarter last year (Q3FY24).
In contrast, revenue grew by 14.5% YoY to ₹533 crore, compared to ₹466 crore in the previous year’s corresponding period, reflecting strong demand across key markets.
Operationally, the pharmaceutical company showed robust improvement, with EBITDA more than doubling to ₹85.2 crore, significantly higher than ₹31.6 crore in Q3FY24.The EBITDA margin also expanded to 16%, up from 7% a year ago, highlighting improved cost efficiencies and better pricing strategies.
Also read: Abbott India Q3 Results: Pharma stock surges over 6% on steady earnings growth
Unichem Laboratories, headquartered in Mumbai, is a major player in the Indian pharmaceutical sector, with a strong presence in regulated markets such as the US and Europe.
Shares of Unichem Laboratories were trading higher following the results, up 2.17% at ₹739.05 per share on the BSE around 1:43 PM.
